Privatlivspræferencer
Inderes bruger cookies for at give en bedre brugeroplevelse og en personlig service. Ved at give samtykke til brugen af cookies kan vi udvikle en endnu bedre service og vil kunne levere indhold, der er interessant for dig.
  • Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Annexin Pharmaceuticals

13,10 SEK-2,96 %9.9, 17.29
Mindre end 1K følgere

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorernes syn
Sammenligne
-2,96 %
+3,56 %
+2,29 %
-8,29 %
-32,84 %
-52,51 %
-67,89 %
-86,27 %
-95,84 %

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Læs mere
Markedsværdi
114,21 mio. SEK
Aktieomsætning
65,51 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
Alle
Selskabsmeddelelser
ViserAlle indholdstyper

Finanskalender
22.10
2026

Delårsrapport Q3'26

11.2
2027

Årsrapport '26

Pressemeddelelse25.08.2026, 17.35

Redeye: Annexin (Q2 Review): Further data expected in H2

Annexin Pharmaceuticals
Pressemeddelelse21.08.2026, 08.00

Annexin advances the NEXUS study to include patients who received an anti-VEGF injection

Annexin Pharmaceuticals
Pressemeddelelse20.08.2026, 08.30

Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV

Annexin Pharmaceuticals

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse21.07.2026, 08.30

Annexin updates on nine patients treated in NEXUS study

Annexin Pharmaceuticals
Selskabsmeddelelse03.07.2026, 13.15

Annexin's rights issue 98 percent subscribed

Annexin Pharmaceuticals
Pressemeddelelse23.06.2026, 08.30

Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO

Annexin Pharmaceuticals
Selskabsmeddelelse15.06.2026, 08.30

The subscription period in Annexin Pharmaceuticals’ rights issue begins today

Annexin Pharmaceuticals
Selskabsmeddelelse10.06.2026, 08.30

Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue

Annexin Pharmaceuticals
Pressemeddelelse05.06.2026, 08.30

Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10

Annexin Pharmaceuticals
Selskabsmeddelelse03.06.2026, 22.50

Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million

Annexin Pharmaceuticals
Pressemeddelelse21.05.2026, 08.30

Annexin investigates a three-day ANXV treatment regimen in patients with RVO

Annexin Pharmaceuticals
Pressemeddelelse11.05.2026, 08.30

Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study

Annexin Pharmaceuticals
Pressemeddelelse24.04.2026, 09.40

Redeye: Annexin Pharmaceuticals (Q1 review): Study on track

Annexin Pharmaceuticals
Pressemeddelelse22.04.2026, 08.30

Annexin accelerates patient recruitment – five patients treated

Annexin Pharmaceuticals
Selskabsmeddelelse13.04.2026, 13.29

Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026

Annexin Pharmaceuticals
Pressemeddelelse06.02.2026, 15.17

Redeye: Annexin Pharmaceuticals (Q4 review): Phase II study away, with positive initial results

Annexin Pharmaceuticals
Selskabsmeddelelse04.02.2026, 14.36

Favourable findings in Annexin’s ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion

Annexin Pharmaceuticals
Selskabsmeddelelse29.01.2026, 08.30

Annexin engages Pareto Securities as liquidity provider

Annexin Pharmaceuticals
Pressemeddelelse19.12.2025, 10.25

BioStock: Annexin has laid the foundation for continued clinical development

Annexin Pharmaceuticals
Pressemeddelelse18.12.2025, 12.30

Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion

Annexin Pharmaceuticals